Raptor adds new member to board of directors
NOVATO, Calif. Drug maker Raptor Pharmaceutical Corp. announced Thursday the appointment of Light Sciences Oncology CEO and president Llew Keltner to its board of directors.
In his new position at Raptor, Keltner will help with the design and execution of clinical trials of drugs for treating genetic diseases and cancer.
“With over 30 years in the healthcare industry, Dr. Keltner’s expertise in genetic analyses will be extremely valuable as we work to advance our development programs in various indications, including cancers, genetic diseases and liver disorders,” Raptor CEO Christopher Starr said in a statement. “Dr. Keltner has also advised healthcare and financial companies through the challenges of raising capital and obtaining approval of new pharmacologic entities.”
Raptor, which recently listed on the NASDAQ, has several drug candidates in clinical development for treating Huntington’s disease, non-alcoholic steatohepatitis and other conditions.
Clinical trial results conclude Novartis’ MS drug yields ‘significant’ results
BASEL, Switzerland Patients taking an investigational drug for multiple sclerosis experienced “significant” reductions in relapses and disability progression, according to results of a late-stage clinical trial released Wednesday.
Novartis said initial results of a phase 3 study of the oral MS drug FTY720 (fingolimod) reduced relapse rates by 54% to 60%, compared to placebo, and reduced disability progression by 30% to 32%.
The company said the reduction in relapses was greater than in patients taking interferon beta-1a, a standard of care. A biologic, interferon beta-1a is marketed in various forms under such brand names as Biogen Idec’s Avonex, Merck KGaA’s Rebif and Bayer HealthCare’s Betaseron.
“We are proud to have reached this critical milestone in the development of FTY720, a novel oral therapy that has the potential to transform the treatment of this ultimately disabling disease,” Novartis Pharma global head of development Trevor Mundel said in a statement.
Study finds diabetes most prevalent in southern United States
NEW YORK Diabetes prevalence is highest in the Southern and Appalachian states, and lowest in the Midwest and the Northeast of America, a new study found.
Researchers writing in BioMed Central’s open access journal Population Health Metrics used two public data sources to investigate the prevalence of diagnosed and undiagnosed diabetes mellitus at the state level.
Goodarz Danaei, from the Harvard School of Public Health in Boston, worked with a team of researchers to combine the data from the National Health and Nutrition Examination Survey and the Behavioral Risk Factor Surveillance System.
“Diabetes mellitus is the sixth leading cause of death in the United States, accounting for approximately 70,000 annual deaths,” Danaei said. “To our knowledge, this is the first study to estimate what the true level of diabetes disease is in every state and how the different states perform in terms of diagnosed versus undiagnosed diabetes.”
Age-standardized diabetes prevalence was highest in Mississippi, West Virginia, Louisiana, Texas, South Carolina, Alabama and Georgia, ranging from 15.8% to 16.6% for men and 12.4% to 14.8% for women. The lowest prevalences were found in Vermont, Minnesota, Montana, and Colorado, just 7% for women in the Northeast and some Western states. These results currently provide the only estimates of total diabetes and undiagnosed diabetes in U.S. states.
According to Danaei, “States like Mississippi and Alabama with the highest estimated diabetes prevalence in our analysis also have the highest levels of blood pressure and cardiovascular disease risk. This concentration of cardiovascular risks and diabetes points to the need for lifestyle and health care interventions in these states.”
The researchers hope their figures will provide motivation, guidance, and benchmarks for designing, implementing, and evaluating diabetes prevention and state level control programs at the state level.